The Myeloma Trial Finder lists clinical trials which are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.

It provides information about clinical trials in the UK. Trials included are not necessarily endorsed by Myeloma UK.

Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on 0800 980 3332

Recruitment to clinical trials may be paused at some hospitals due to the COVID-19 pandemic. Your healthcare team can provide additional details about recruitment to clinical trials in your area.

There are currently 22 open trials. In 107 locations

What is a Clinical Trial?

Step 2: Choose a Trial

There are currently 22 open trials

Step 3: View Details

Trial Title:

Teclistamab for relapsed and refractory myeloma

Treatments:

Teclistamab

Myeloma stage:

Relapsed, Refractory

Trial phase:

II

Summary

Summary:

This trial is investigating whether a drug called teclistamab is safe and effective for the treatment of relapsed and/or refractory myeloma patients.

Teclistamab is is a new type of immunotherapy called a bispecific antibody. It works by helping your T-cells (a type of immune cells) find and kill myeloma cells.

Locations

Locations:

University College Hospital, London;
The Royal Marsden Hospital, Sutton

Who can enter the study?

Who can enter the study?:

Relapsed and/or refractory myeloma patients who have received at least three lines of treatment including an immunomodulatory drug (e.g. lenalidomide (Revlimid)), a proteasome inhibitor (e.g. bortezomib (Velcade)) and an anti-CD38 monoclonal antibody (e.g. daratumumab (Darzalex)).

What's involved?

What's involved?:

Patients will be given teclistamab subcutaneously (injection into the skin).

Patients will be required to attend outpatient clinics for regular check-ups and blood tests.

Clinical Information

Clinical Information
(for Medical Professionals):

A Phase II, open-label clinical trial evaluating the safety and efficacy of teclistamab for relapsed and/or refractory myeloma.

For more information, click here.

Find

Find out more about Myeloma UK:

Visit www.myeloma.org.uk

Do you want to talk to someone? Call our myeloma Infoline